PRKCD — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Balanol (SCHEMBL62128)	1.00	17/20
Balanol (SCHEMBL62129)	1.00	17/20
Staurosporine (SCHEMBL8156)	1.00	10/20
Staurosporine (SCHEMBL8157)	1.00	10/20
SCHEMBL1255	0.61	9/20
SCHEMBL1704	0.64	7/20
Fasudil (SCHEMBL4674)	1.00	6/20
SCHEMBL1442	0.78	6/20
SCHEMBL1465	0.73	6/20
SCHEMBL1365	0.66	6/20
SCHEMBL9306	0.89	5/20
SCHEMBL9838	0.79	5/20
SCHEMBL9469	0.75	5/20
SCHEMBL1762	0.74	5/20
SCHEMBL9338	0.70	5/20
SCHEMBL1977	0.67	5/20
SCHEMBL1522	1.00	4/20
SCHEMBL9197	1.00	4/20
SCHEMBL9588	1.00	4/20
Ripasudil (SCHEMBL31542)	1.00	4/20

Clinical trials — most relevant to PRKCD by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Metformin and Simvastatin Use in Bladder Cancer	PHASE2	UNKNOWN
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Fat Induced Insulin Resistance and Atherosclerosis	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKCD binder may also engage these)

Protein	Name	Similarity
P09215	—	1.000	P09215 →
Q5PU49	—	1.000	Q5PU49 →
Q02111	—	1.000	Q02111 →
P13678	—	1.000	P13678 →
PRKCQ	Protein kinase C theta type	1.000	landscape →
P28867	—	1.000	P28867 →
P34885	—	1.000	P34885 →
Q16975	—	1.000	Q16975 →
Q9WTQ0	—	1.000	Q9WTQ0 →
PRKCE	Protein kinase C epsilon type	0.998	landscape →
P34722	—	0.997	P34722 →
P13677	—	0.997	P13677 →
P10830	—	0.996	P10830 →
Q6PFQ0	—	0.996	Q6PFQ0 →
P09216	—	0.996	P09216 →
PRKCH	Protein kinase C eta type	0.996	landscape →
P16054	—	0.995	P16054 →
P05130	—	0.995	P05130 →
Q64617	—	0.994	Q64617 →
Q5R4K9	—	0.994	Q5R4K9 →
Q62074	—	0.993	Q62074 →
Q90XF2	—	0.993	Q90XF2 →
O19111	—	0.993	O19111 →
P23298	—	0.993	P23298 →
Q19266	—	0.993	Q19266 →
PRKCA	Protein kinase C alpha type	0.993	landscape →
F1M7Y5	—	0.993	F1M7Y5 →
Q12706	—	0.992	Q12706 →
Q8BRK8	—	0.992	Q8BRK8 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	0.992	landscape →